AAPL VS BMRN Stock Comparison
Performance
AAPL100/100
100/100
AAPL returned 13.51% in the last 12 months. Based on SPY's performance of -13.31%, its performance is above average giving it a score of 100 of 100.
BMRN10/100
10/100
BMRN returned -2.11% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
AAPL78/100
78/100
38 analysts offer 12-month price targets for AAPL. Together, they have an average target of 190.63, the most optimistic target put AAPL at 240 within 12-months and the most pessimistic has AAPL at 110.
BMRN77/100
77/100
24 analysts offer 12-month price targets for BMRN. Together, they have an average target of 117.1, the most optimistic target put BMRN at 135 within 12-months and the most pessimistic has BMRN at 102.
Sentiment
AAPL70/100
70/100
AAPL had a bullish sentiment score of 70.31% across Twitter and StockTwits over the last 12 months. It had an average of 3,037.82 posts, 116,437.71 comments, and 721,824.29 likes per day.
BMRN
"Sentiment" not found for BMRN
Technicals
AAPL18/100
18/100
AAPL receives a 17 of 100 based on 14 indicators. 2 are bullish, 11 are bearish.
BMRN50/100
50/100
BMRN receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.
Earnings
AAPL100/100
100/100
AAPL has missed earnings 1 times in the last 20 quarters.
BMRN69/100
69/100
BMRN has missed earnings 2 times in the last 20 quarters.
Profit
AAPL76/100
76/100
Out of the last 20 quarters, AAPL has had 20 profitable quarters and has increased their profits year over year on 10 of them.
BMRN61/100
61/100
Out of the last 20 quarters, BMRN has had 12 profitable quarters and has increased their profits year over year on 8 of them.
Volatility
AAPL45/100
45/100
AAPL has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.
BMRN51/100
51/100
BMRN has had a higher than average amount of volatility over the last 12 months giving it a score of 50 of 100.
Dividend
AAPL50/100
50/100
AAPL's most recent dividend was $0.18 per share, based on a share price of $168.22. It was a payout ratio of 24.99% compared to their total earnings.
BMRN
"Dividend" not found for BMRN
All score calculations are broken down here to help you make more informed investing decisions
Apple Inc. Summary
Nasdaq / AAPL
Technology
Consumer Electronics
Apple Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide. The company offers iPhone, a line of smartphones; Mac, a line of personal computers; iPad, a line of multi-purpose tablets; and wearables, home, and accessories comprising AirPods, Apple TV, Apple Watch, Beats products, and HomePod. It also provides AppleCare support and cloud services; and operates various platforms, including the App Store that allow customers to discover and download applications and digital content, such as books, music, video, games, and podcasts. In addition, the company offers various services, such as Apple Arcade, a game subscription service; Apple Fitness+, a personalized fitness service; Apple Music, which offers users a curated listening experience with on-demand radio stations; Apple News+, a subscription news and magazine service; Apple TV+, which offers exclusive original content; Apple Card, a co-branded credit card; and Apple Pay, a cashless payment service, as well as licenses its intellectual property. The company serves consumers, and small and mid-sized businesses; and the education, enterprise, and government markets. It distributes third-party applications for its products through the App Store. The company also sells its products through its retail and online stores, and direct sales force; and third-party cellular network carriers, wholesalers, retailers, and resellers. Apple Inc. was incorporated in 1977 and is headquartered in Cupertino, California.
BioMarin Pharmaceuticals Inc Summary
Nasdaq / BMRN
Healthcare
Biotechnology
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare AAPL to other companies in the same or a similar industry.